Obstet Gynecol Sci.  2016 Nov;59(6):506-511. 10.5468/ogs.2016.59.6.506.

Study of dienogest for dysmenorrhea and pelvic pain associated with endometriosis

• Kim SA
• Um MJ
• Kim HK
• Kim SJ
• Moon SJ
• Jung H

• KMID: 2378575
• DOI: http://doi.org/10.5468/ogs.2016.59.6.506

Abstract

OBJECTIVE
To evaluate the effect of orally administered dienogest (DNG) for dysmenorrhea and pelvic pain associated with endometriosis.
METHODS
For this study we recruited 89 patients with dysmenorrhea and pelvic pain associated with endometriosis diagnosed by laparoscopy. All patients complained of persistent dysmenorrhea and pelvic pain despite surgical treatment 6 months previously. After 6 months of DNG treatment, we used a 0 to 3 point verbal rating scale to measure the severity of disability in daily life due to dysmenorrhea and pelvic pain, and the use of analgesics. Weight gain, serum lipid and liver enzyme tests were performed before treatment and after 6 months of DNG treatment.
RESULTS
Total dysmenorrhea scores assessed by the verbal rating scale significantly decreased by the end of treatment (P<0.001). The mean (±standard deviation) pain score for dysmenorrhea before and after treatment were 1.42±1.1 and 0.1±0.3, respectively. The mean non-menstrual pelvic pain scores before and after treatment were 0.52±0.6 and 0.18±0.3, respectively, showing a significant difference (P<0.001). The use of analgesics significantly decreased by the end of the treatment (P<0.001). The associated adverse effects were weight gains (in 56 of 89 patients, 63%) and uterine bleeding (in 28 of 89 patients, 31.5%). The weight gain (before treatment, 57.9±9.7; after treatment, 61.1±12.6) was statistically significant (P<0.040).
CONCLUSION
This study demonstrated that orally administered DNG could be used to effectively treat dysmenorrhea and pelvic pain associated with endometriosis although the side effects of weight gain and uterine bleeding should be considered.

Keyword

Dienogest; Dysmenorrhea; Endometriosis

MeSH Terms

Analgesics
Dysmenorrhea*
Endometriosis*
Female
Humans
Laparoscopy
Liver
Pelvic Pain*
Uterine Hemorrhage
Weight Gain
Analgesics

Reference

1. Harada T, Momoeda M, Taketani Y, Hoshiai H, Terakawa N. Low-dose oral contraceptive pill for dysmenorrhea associated with endometriosis: a placebo-controlled, double-blind, randomized trial. Fertil Steril. 2008; 90:1583–1588.

2. Olive DL, Pritts EA. Treatment of endometriosis. N Engl J Med. 2001; 345:266–275.

3. Crosignani P, Olive D, Bergqvist A, Luciano A. Advances in the management of endometriosis: an update for clinicians. Hum Reprod Update. 2006; 12:179–189.

4. Sasagawa S, Shimizu Y, Kami H, Takeuchi T, Mita S, Imada K, et al. Dienogest is a selective progesterone receptor agonist in transactivation analysis with potent oral endometrial activity due to its efficient pharmacokinetic profile. Steroids. 2008; 73:222–231.

5. Oettel M, Breitbarth H, Elger W, Graser T, Hubler D, Kaufmann G, et al. The pharmacological profile of dienogest. Eur J Contracept Reprod Health Care. 1999; 4:Suppl 1. 2–13.

6. McCormack PL. Dienogest: a review of its use in the treatment of endometriosis. Drugs. 2010; 70:2073–2088.

7. Revised American Society for Reproductive Medicine classification of endometriosis: 1996. Fertil Steril. 1997; 67:817–821.

8. Biberoglu KO, Behrman SJ. Dosage aspects of danazol therapy in endometriosis: short-term and long-term effectiveness. Am J Obstet Gynecol. 1981; 139:645–654.

9. Andersch B, Milsom I. An epidemiologic study of young women with dysmenorrhea. Am J Obstet Gynecol. 1982; 144:655–660.

10. Petta CA, Matos AM, Bahamondes L, Faundes D. Current practice in the management of symptoms of endometriosis: a survey of Brazilian gynecologists. Rev Assoc Med Bras (1992). 2007; 53:525–529.

11. Sitruk-Ware R. New progestogens: a review of their effects in perimenopausal and postmenopausal women. Drugs Aging. 2004; 21:865–883.

12. Harada T, Momoeda M, Taketani Y, Aso T, Fukunaga M, Hagino H, et al. Dienogest is as effective as intranasal buserelin acetate for the relief of pain symptoms associated with endometriosis: a randomized, double-blind, multicenter, controlled trial. Fertil Steril. 2009; 91:675–681.

13. Alkatout I, Mettler L, Beteta C, Hedderich J, Jonat W, Schollmeyer T, et al. Combined surgical and hormone therapy for endometriosis is the most effective treatment: prospective, randomized, controlled trial. J Minim Invasive Gynecol. 2013; 20:473–481.

14. Dallenbach-Hellweg G. The influence of contraceptive steroids on the histological appearance of the endometrium. In : Diczfalusy E, Fraser IS, Webb FT, editors. Endometrial bleeding and steroidal contraception. Bath: Pitman Press;1980. p. 153–173.

15. Horie S, Harada T, Mitsunari M, Taniguchi F, Iwabe T, Terakawa N. Progesterone and progestational compounds attenuate tumor necrosis factor alpha-induced interleukin-8 production via nuclear factor kappa B inactivation in endometriotic stromal cells. Fertil Steril. 2005; 83:1530–1535.

16. Strowitzki T, Marr J, Gerlinger C, Faustmann T, Seitz C. Detailed analysis of a randomized, multicenter, comparative trial of dienogest versus leuprolide acetate in endometriosis. Int J Gynaecol Obstet. 2012; 117:228–233.

17. Zeun S, Lu M, Uddin A, Zeiler B, Morrison D, Blode H. Pharmacokinetics of an oral contraceptive containing oestradiol valerate and dienogest. Eur J Contracept Reprod Health Care. 2009; 14:221–232.

18. Endrikat J, Parke S, Trummer D, Schmidt W, Duijkers I, Klipping C. Ovulation inhibition with four variations of a four-phasic estradiol valerate/dienogest combined oral contraceptive: results of two prospective, randomized, open-label studies. Contraception. 2008; 78:218–225.

19. Cosson M, Querleu D, Donnez J, Madelenat P, Konincks P, Audebert A, et al. Dienogest is as effective as triptorelin in the treatment of endometriosis after laparoscopic surgery: results of a prospective, multicenter, randomized study. Fertil Steril. 2002; 77:684–692.

20. Fraser IS. Bleeding arising from the use of exogenous steroids. Baillieres Best Pract Res Clin Obstet Gynaecol. 1999; 13:203–222.